Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gleave

Showing results (751-760 of 839) with videos related to

Pageof 84
Sort By:
Nature|July 21, 2022
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancerCameron Herberts, Matti Annala, Joonatan Sipola, et al.
European Urology|April 12, 2011
Active surveillance of small renal masses: progression patterns of early stage kidney cancerMichael A S Jewett, Kamal Mattar, Joan Basiuk, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
Prostate Cancer and Prostatic Diseases|May 4, 2016
Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomiesM S Tretiakova, W Wei, H D Boyer, et al.
Urologic Oncology|July 7, 2020
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancerDaniel H Kwon, Li Zhang, David A Quigley, et al.
Epigenomics|September 3, 2024
The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directionsYuzhuo Wang, Joshua Scurll, Itzel Astiazarán Rascón, et al.
Cancer Research|December 21, 2013
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug developmentDong Lin, Alexander W Wyatt, Hui Xue, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L Lotan, Wei Wei, Olga Ludkovski, et al.
Gigascience|May 15, 2018
The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implicationsVarune Rohan Ramnarine, Mohammed Alshalalfa, Fan Mo, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
Pageof 84

Showing results (751-760 of 839) with videos related to

Sort By:
Pageof 84
Nature|July 21, 2022
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancerCameron Herberts, Matti Annala, Joonatan Sipola, et al.
European Urology|April 12, 2011
Active surveillance of small renal masses: progression patterns of early stage kidney cancerMichael A S Jewett, Kamal Mattar, Joan Basiuk, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
Prostate Cancer and Prostatic Diseases|May 4, 2016
Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomiesM S Tretiakova, W Wei, H D Boyer, et al.
Urologic Oncology|July 7, 2020
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancerDaniel H Kwon, Li Zhang, David A Quigley, et al.
Epigenomics|September 3, 2024
The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directionsYuzhuo Wang, Joshua Scurll, Itzel Astiazarán Rascón, et al.
Cancer Research|December 21, 2013
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug developmentDong Lin, Alexander W Wyatt, Hui Xue, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 14, 2016
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISHTamara L Lotan, Wei Wei, Olga Ludkovski, et al.
Gigascience|May 15, 2018
The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implicationsVarune Rohan Ramnarine, Mohammed Alshalalfa, Fan Mo, et al.
JAMA|May 30, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate CancerLisa F Newcomb, Jeannette M Schenk, Yingye Zheng, et al.
Pageof 84